🇺🇸 FOLLITROPIN ALFA in United States

383 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Ovarian Hyperstimulation Syndrome — 163 reports (42.56%)
  2. Ascites — 42 reports (10.97%)
  3. Off Label Use — 33 reports (8.62%)
  4. Abdominal Distension — 28 reports (7.31%)
  5. Abdominal Pain — 25 reports (6.53%)
  6. Nausea — 21 reports (5.48%)
  7. Drug Ineffective — 19 reports (4.96%)
  8. Maternal Exposure During Pregnancy — 18 reports (4.7%)
  9. Dyspnoea — 17 reports (4.44%)
  10. Pleural Effusion — 17 reports (4.44%)

Source database →

FOLLITROPIN ALFA in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is FOLLITROPIN ALFA approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for FOLLITROPIN ALFA in United States?

Marketing authorisation holder not available in our data.